{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:22:15Z","timestamp":1792592535066,"version":"4.5.0"},"reference-count":191,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.addr.2022.114177","type":"journal-article","created":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T10:37:38Z","timestamp":1646131058000},"page":"114177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":138,"special_numbering":"C","title":["Tumor-activated carrier-free prodrug nanoparticles for targeted cancer Immunotherapy: Preclinical evidence for safe and effective drug delivery"],"prefix":"10.1016","volume":"183","author":[{"given":"Man","family":"Kyu Shim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suah","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Cheol","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwangmeyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2022.114177_b0005","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.addr.2017.04.011","article-title":"Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy","volume":"114","author":"Francis","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2022.114177_b0010","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.addr.2017.05.011","article-title":"Delivering safer immunotherapies for cancer","volume":"114","author":"Milling","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"11","key":"10.1016\/j.addr.2022.114177_b0015","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/nrclinonc.2017.88","article-title":"Monitoring immune-checkpoint blockade: response evaluation and biomarker development","volume":"14","author":"Nishino","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.addr.2022.114177_b0020","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2022.114177_b0025","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cell.2017.05.035","article-title":"Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing","volume":"169","author":"Zheng","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.addr.2022.114177_b0030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.addr.2022.114177_b0035","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1021\/nn5062029","article-title":"Nanoparticle-Based Immunotherapy for Cancer","volume":"9","author":"Shao","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2022.114177_b0040","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.addr.2022.114177_b0045","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"1","key":"10.1016\/j.addr.2022.114177_b0050","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic Cell Death in Cancer Therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu. Rev. Immunol."},{"issue":"8","key":"10.1016\/j.addr.2022.114177_b0055","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1111\/jcmm.14356","article-title":"Immunogenic cell death in cancer therapy: Present and emerging inducers","volume":"23","author":"Zhou","year":"2019","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.addr.2022.114177_b0060","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nrc3380","article-title":"Immunogenic cell death and DAMPs in cancer therapy","volume":"12","author":"Krysko","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2022.114177_b0065","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.it.2007.08.004","article-title":"Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox","volume":"28","author":"Rubartelli","year":"2007","journal-title":"Trends Immunol."},{"issue":"5","key":"10.1016\/j.addr.2022.114177_b0070","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1038\/emm.2017.52","article-title":"Engulfment signals and the phagocytic machinery for apoptotic cell clearance","volume":"49","author":"Park","year":"2017","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.addr.2022.114177_b0075","doi-asserted-by":"crossref","first-page":"1804688","DOI":"10.1002\/adfm.201804688","article-title":"Recent Progresses in Phototherapy-Synergized Cancer Immunotherapy","volume":"28","author":"Ng","year":"2018","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.addr.2022.114177_b0080","doi-asserted-by":"crossref","first-page":"11249","DOI":"10.1021\/acsnano.9b04315","article-title":"Enzyme-driven membrane-targeted chimeric peptide for enhanced tumor photodynamic immunotherapy","volume":"13","author":"Zhang","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2022.114177_b0085","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s12272-019-01150-z","article-title":"Natural compound inducers of immunogenic cell death","volume":"42","author":"Diederich","year":"2019","journal-title":"Arch Pharm Res"},{"issue":"3","key":"10.1016\/j.addr.2022.114177_b0090","doi-asserted-by":"crossref","first-page":"e27878","DOI":"10.4161\/onci.27878","article-title":"Trial Watch","volume":"3","author":"Vacchelli","year":"2014","journal-title":"OncoImmunology"},{"issue":"24","key":"10.1016\/j.addr.2022.114177_b0095","doi-asserted-by":"crossref","first-page":"2101840","DOI":"10.1002\/advs.202101840","article-title":"Microenvironment\u2010responsive prodrug\u2010induced pyroptosis boosts cancer immunotherapy","volume":"8","author":"Xiao","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.addr.2022.114177_b0100","doi-asserted-by":"crossref","first-page":"1803001","DOI":"10.1002\/adma.201803001","article-title":"Binary cooperative prodrug nanoparticles improve immunotherapy by synergistically modulating immune tumor microenvironment","volume":"30","author":"Feng","year":"2018","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2022.114177_b0105","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1002\/anie.201914453","article-title":"Diselenide-pemetrexed assemblies for combined cancer immuno-, radio-, and chemotherapies","volume":"59","author":"Li","year":"2020","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.addr.2022.114177_b0110","doi-asserted-by":"crossref","first-page":"2007882","DOI":"10.1002\/smll.202007882","article-title":"Engineering oxaliplatin prodrug nanoparticles for second near-infrared fluorescence imaging-guided immunotherapy of colorectal cancer","volume":"17","author":"Zhu","year":"2021","journal-title":"Small"},{"key":"10.1016\/j.addr.2022.114177_b0115","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nbt0415-321","article-title":"IDO inhibitors move center stage in immuno-oncology","volume":"33","author":"Sheridan","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2022.114177_b0120","doi-asserted-by":"crossref","first-page":"8065","DOI":"10.1158\/0008-5472.CAN-05-2213","article-title":"Marrying immunotherapy with chemotherapy: why say IDO?","volume":"65","author":"Muller","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2022.114177_b0125","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.addr.2022.114177_b0130","doi-asserted-by":"crossref","first-page":"9082","DOI":"10.1200\/JCO.2017.35.15_suppl.9082","article-title":"Clinical outcomes of patients with non-small cell lung cancer (NSCLC) receiving chemotherapy after immune checkpoint blockade","volume":"35","author":"Grigg","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.addr.2022.114177_b0135","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.addr.2012.06.012","article-title":"Tumor-targeting multi-functional nanoparticles for theragnosis: new paradigm for cancer therapy","volume":"64","author":"Ryu","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"25","key":"10.1016\/j.addr.2022.114177_b0140","doi-asserted-by":"crossref","first-page":"7906","DOI":"10.7150\/thno.38425","article-title":"Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy","volume":"9","author":"Lim","year":"2019","journal-title":"Theranostics"},{"issue":"19","key":"10.1016\/j.addr.2022.114177_b0145","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1039\/D1TB00397F","article-title":"Rediscovery of nanoparticle-based therapeutics: boosting immunogenic cell death for potential application in cancer immunotherapy","volume":"9","author":"Yang","year":"2021","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.addr.2022.114177_b0150","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2019.07.009","article-title":"Optimizing advances in nanoparticle delivery for cancer immunotherapy","volume":"144","author":"Caster","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1-2","key":"10.1016\/j.addr.2022.114177_b0155","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijpharm.2017.01.055","article-title":"Hydrophobically modified polysaccharide-based on polysialic acid nanoparticles as carriers for anticancer drugs","volume":"520","author":"Jung","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2022.114177_b0160","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat. Rev. Mater."},{"issue":"5","key":"10.1016\/j.addr.2022.114177_b0165","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nnano.2008.114","article-title":"Seven challenges for nanomedicine","volume":"3","author":"Sanhai","year":"2008","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.addr.2022.114177_b0170","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jconrel.2017.09.015","article-title":"Effects of tumor microenvironments on targeted delivery of glycol chitosan nanoparticles","volume":"267","author":"Yhee","year":"2017","journal-title":"J. Control. Release"},{"issue":"7","key":"10.1016\/j.addr.2022.114177_b0175","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1158\/1078-0432.CCR-18-3724","article-title":"Mapping physical tumor microenvironment and drug delivery","volume":"25","author":"Nia","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.addr.2022.114177_b0180","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.devcel.2010.05.012","article-title":"Tumors as organs: complex tissues that interface with the entire organism","volume":"18","author":"Egeblad","year":"2010","journal-title":"Dev. Cell"},{"key":"10.1016\/j.addr.2022.114177_b0185","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2967\/jnumed.109.065706","article-title":"Of mice and humans: are they the same?-Implications in cancer translational research","volume":"51","author":"de Jong","year":"2010","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.addr.2022.114177_b0190","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.addr.2022.114177_b0195","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag2942","article-title":"Anti\u2013PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM","volume":"8","author":"Mathios","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2022.114177_b0200","doi-asserted-by":"crossref","unstructured":"M. Baghdadi, H. Wada, S. Nakanishi, H. Abe, N. Han, W.E. Putra, D. Endo, H. Watari, N. Sakuragi, Y.J.C.r. Hida, Chemotherapy-induced IL34 enhances immunosuppression by tumor-associated macrophages and mediates survival of chemoresistant lung cancer cells, 76 (2016) 6030-6042.","DOI":"10.1158\/0008-5472.CAN-16-1170"},{"key":"10.1016\/j.addr.2022.114177_b0205","doi-asserted-by":"crossref","first-page":"6631","DOI":"10.1158\/0008-5472.CAN-15-3034","article-title":"Doxorubicin-Induced Systemic Inflammation Is Driven by Upregulation of Toll-Like Receptor TLR4 and Endotoxin Leakage","volume":"76","author":"Wang","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2022.114177_b0210","doi-asserted-by":"crossref","unstructured":"G. Lombardi, E. Rumiato, R. Bertorelle, D. Saggioro, P. Farina, A. Della Puppa, F. Zustovich, F. Berti, V. Sacchetto, R.J.A.j.o.c.o. Marcato, Clinical and genetic factors associated with severe hematological toxicity in glioblastoma patients during radiation plus temozolomide treatment, 38 (2015) 514-519.","DOI":"10.1097\/COC.0b013e3182a790ea"},{"key":"10.1016\/j.addr.2022.114177_b0215","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.addr.2016.04.025","article-title":"Challenges and strategies in anti-cancer nanomedicine development: an industry perspective","volume":"108","author":"Hare","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2022.114177_b0220","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrd.2018.46","article-title":"The expanding role of prodrugs in contemporary drug design and development","volume":"17","author":"Rautio","year":"2018","journal-title":"Nat. Rev. Drug Discovery"},{"key":"10.1016\/j.addr.2022.114177_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120557","article-title":"Advances and perspectives in carrier-free nanodrugs for cancer chemo-monotherapy and combination therapy","volume":"268","author":"Huang","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2022.114177_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113994","article-title":"Delivering more for less: nanosized, minimal-carrier and pharmacoactive drug delivery systems","volume":"179","author":"Etter","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2022.114177_b0235","doi-asserted-by":"crossref","first-page":"2002365","DOI":"10.1002\/advs.202002365","article-title":"Engineering prodrug nanomedicine for cancer immunotherapy","volume":"7","author":"Yang","year":"2020","journal-title":"Adv. Sci."},{"issue":"52","key":"10.1016\/j.addr.2022.114177_b0240","doi-asserted-by":"crossref","first-page":"2101460","DOI":"10.1002\/smll.202101460","article-title":"Small\u2010molecule prodrug nanoassemblies: an emerging nanoplatform for anticancer drug delivery","volume":"17","author":"Li","year":"2021","journal-title":"Small"},{"key":"10.1016\/j.addr.2022.114177_b0245","first-page":"220","article-title":"Carrier-free nanodrugs with efficient drug delivery and release for cancer therapy: from intrinsic physicochemical properties to external modification","volume":"8","author":"Mei","year":"2022","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.addr.2022.114177_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120347","article-title":"Cancer-specific drug-drug nanoparticles of pro-apoptotic and cathepsin B-cleavable peptide-conjugated doxorubicin for drug-resistant cancer therapy","volume":"261","author":"Shim","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2022.114177_b0255","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.addr.2012.01.002","article-title":"Enzyme-responsive nanoparticles for drug release and diagnostics","volume":"64","author":"de la Rica","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2022.114177_b0260","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jconrel.2019.07.004","article-title":"Enzyme responsive drug delivery systems in cancer treatment","volume":"308","author":"Shahriari","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2022.114177_b0265","unstructured":"A. Illanes, Enzyme Biocatalysis: Principles and Applications, Springer."},{"key":"10.1016\/j.addr.2022.114177_b0270","doi-asserted-by":"crossref","first-page":"8612","DOI":"10.1002\/anie.201004253","article-title":"An enzyme-responsive polymeric superamphiphile","volume":"49","author":"Wang","year":"2010","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.addr.2022.114177_b0275","doi-asserted-by":"crossref","unstructured":"S. Lee, J. Xie, X.J.B. Chen, Peptide-based probes for targeted molecular imaging, 49 (2010) 1364-1376.","DOI":"10.1021\/bi901135x"},{"key":"10.1016\/j.addr.2022.114177_b0280","doi-asserted-by":"crossref","unstructured":"H. Koo, M.S. Huh, I.-C. Sun, S.H. Yuk, K. Choi, K. Kim, I.C.J.A.o.c.r. Kwon, In vivo targeted delivery of nanoparticles for theranosis, 44 (2011) 1018-1028.","DOI":"10.1021\/ar2000138"},{"key":"10.1016\/j.addr.2022.114177_b0285","first-page":"23","article-title":"Targeting cathepsin B for cancer therapies","volume":"56","author":"Ruan","year":"2015","journal-title":"Horiz Cancer Res"},{"key":"10.1016\/j.addr.2022.114177_b0290","first-page":"1349","article-title":"Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer (review)","volume":"5","author":"Kos","year":"1998","journal-title":"Oncol Rep"},{"key":"10.1016\/j.addr.2022.114177_b0295","doi-asserted-by":"crossref","unstructured":"T. Reinheckel, J. Deussing, W. Roth, C. Peters, Towards Specific Functions of Lysosomal Cysteine Peptidases: Phenotypes of Mice Deficient for Cathepsin \u0392 or Cathepsin L, 382 (2001) 735-742.","DOI":"10.1515\/bchm.2001.382.5.735"},{"key":"10.1016\/j.addr.2022.114177_b0300","first-page":"427","article-title":"Multiple roles in cancer, PROTEOMICS \u2013","volume":"8","author":"Aggarwal","year":"2014","journal-title":"Clinical Applications"},{"key":"10.1016\/j.addr.2022.114177_b0305","doi-asserted-by":"crossref","first-page":"14698","DOI":"10.1002\/anie.201608504","article-title":"Cathepsin B-specific metabolic precursor for in vivo tumor-specific fluorescence imaging","volume":"55","author":"Shim","year":"2016","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.addr.2022.114177_b0310","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3892\/ijo.2012.1754","article-title":"Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review)","volume":"42","author":"Zhong","year":"2013","journal-title":"Int J Oncol"},{"key":"10.1016\/j.addr.2022.114177_b0315","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.addr.2019.01.010","article-title":"Cathepsin-sensitive nanoscale drug delivery systems for cancer therapy and other diseases","volume":"151\u2013152","author":"Dheer","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2022.114177_b0320","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jconrel.2020.08.046","article-title":"Epidermal growth factor (EGF)-based activatable probe for predicting therapeutic outcome of an EGF-based doxorubicin prodrug","volume":"328","author":"Kim","year":"2020","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.addr.2022.114177_b0325","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3390\/pharmaceutics14010083","article-title":"Cathepsin B-overexpressed tumor cell activatable albumin-binding doxorubicin prodrug for cancer-targeted therapy","volume":"14","author":"Cho","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2022.114177_b0330","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jconrel.2018.11.032","article-title":"Carrier-free nanoparticles of cathepsin B-cleavable peptide-conjugated doxorubicin prodrug for cancer targeting therapy","volume":"294","author":"Shim","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2022.114177_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121189","article-title":"The safe and effective intraperitoneal chemotherapy with cathepsin B-specific doxorubicin prodrug nanoparticles in ovarian cancer with peritoneal carcinomatosis","volume":"279","author":"Kim","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2022.114177_b0340","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jconrel.2020.10.065","article-title":"Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance","volume":"330","author":"Kim","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2022.114177_b0345","first-page":"738","article-title":"Caspase 3 in Breast Cancer","volume":"9","author":"O\u2019Donovan","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2022.114177_b0350","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0167-4838(98)00133-2","article-title":"Properties of the caspases, Biochimica et Biophysica Acta (BBA) -","volume":"1387","author":"Stennicke","year":"1998","journal-title":"Protein Structure and Molecular Enzymology"},{"key":"10.1016\/j.addr.2022.114177_b0355","doi-asserted-by":"crossref","unstructured":"A. Thornberry Nancy, Y. Lazebnik, Caspases: Enemies Within, Science, 281 (1998) 1312-1316.","DOI":"10.1126\/science.281.5381.1312"},{"key":"10.1016\/j.addr.2022.114177_b0360","doi-asserted-by":"crossref","first-page":"16635","DOI":"10.1038\/s41598-017-16653-2","article-title":"Caspase-3\/-7-specific metabolic precursor for bioorthogonal tracking of tumor apoptosis","volume":"7","author":"Shim","year":"2017","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.addr.2022.114177_b0365","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/sj.cdd.4400476","article-title":"Emerging roles of caspase-3 in apoptosis","volume":"6","author":"Porter","year":"1999","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.addr.2022.114177_b0370","first-page":"734","article-title":"Chemotherapy augments TRAIL-induced apoptosis in breast cell lines","volume":"59","author":"Keane","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2022.114177_b0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biomaterials.2016.03.043","article-title":"Albumin-binding caspase-cleavable prodrug that is selectively activated in radiation exposed local tumor","volume":"94","author":"Chung","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2022.114177_b0380","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.biomaterials.2017.06.031","article-title":"NIR-triggered high-efficient photodynamic and chemo-cascade therapy using caspase-3 responsive functionalized upconversion nanoparticles","volume":"141","author":"Zhao","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2022.114177_b0385","doi-asserted-by":"crossref","first-page":"1800368","DOI":"10.1002\/advs.201800368","article-title":"Self-triggered apoptosis enzyme prodrug therapy (STAEPT): enhancing targeted therapies via recurrent bystander killing effect by exploiting caspase-cleavable linker","volume":"5","author":"Chung","year":"2018","journal-title":"Adv. Sci."},{"key":"10.1016\/j.addr.2022.114177_b0390","doi-asserted-by":"crossref","first-page":"9585","DOI":"10.1021\/acsnano.9b10144","volume":"14","author":"Wang","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2022.114177_b0395","doi-asserted-by":"crossref","unstructured":"B.S. Lee, Y.W. Cho, G.C. Kim, D.H. Lee, C.J. Kim, H.S. Kil, D.Y. Chi, Y. Byun, S.H. Yuk, K. Kim, I.-S. Kim, I.C. Kwon, S.Y. Kim, Induced Phenotype Targeted Therapy: Radiation-Induced Apoptosis-Targeted Chemotherapy, JNCI: Journal of the National Cancer Institute, 107 (2015) dju403.","DOI":"10.1093\/jnci\/dju403"},{"key":"10.1016\/j.addr.2022.114177_b0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119494","article-title":"Visible light-induced apoptosis activatable nanoparticles of photosensitizer-DEVD-anticancer drug conjugate for targeted cancer therapy","volume":"224","author":"Um","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2022.114177_b0405","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1039\/D0CS00021C","article-title":"Self-assembly of block copolymers towards mesoporous materials for energy storage and conversion systems","volume":"49","author":"Li","year":"2020","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.addr.2022.114177_b0410","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"cAC10-vcMMAE, an anti-CD30\u2013monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.addr.2022.114177_b0415","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1189\/jlb.0607338","article-title":"Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation","volume":"82","author":"Van Lint","year":"2007","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.addr.2022.114177_b0420","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1742-4658.2010.07919.x","article-title":"Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting","volume":"278","author":"Gialeli","year":"2011","journal-title":"The FEBS Journal"},{"key":"10.1016\/j.addr.2022.114177_b0425","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.cardiores.2005.12.002","article-title":"Structure and function of matrix metalloproteinases and TIMPs","volume":"69","author":"Nagase","year":"2006","journal-title":"Cardiovasc. Res."},{"issue":"3","key":"10.1016\/j.addr.2022.114177_b0430","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrc745","article-title":"New functions for the matrix metalloproteinases in cancer progression","volume":"2","author":"Egeblad","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2022.114177_b0435","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jconrel.2015.06.022","article-title":"In vivo evaluation of matrix metalloproteinase responsive silk\u2013elastinlike protein polymers for cancer gene therapy","volume":"213","author":"Price","year":"2015","journal-title":"J. Control. Release"},{"issue":"8","key":"10.1016\/j.addr.2022.114177_b0440","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1021\/acs.bioconjchem.7b00330","article-title":"Matrix Metalloproteinase-Responsive Multifunctional Peptide-Linked Amphiphilic Block Copolymers for Intelligent Systemic Anticancer Drug Delivery","volume":"28","author":"Ke","year":"2017","journal-title":"Bioconjug. Chem."},{"issue":"5","key":"10.1016\/j.addr.2022.114177_b0445","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1021\/acsabm.0c00242","article-title":"Matrix Metalloproteinase-Responsive PEGylated Lipid Nanoparticles for Controlled Drug Delivery in the Treatment of Rheumatoid Arthritis","volume":"3","author":"He","year":"2020","journal-title":"ACS Applied Bio Materials"},{"issue":"31","key":"10.1016\/j.addr.2022.114177_b0450","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1002\/adma.201501803","article-title":"Therapeutic Enzyme-Responsive Nanoparticles for Targeted Delivery and Accumulation in Tumors","volume":"27","author":"Callmann","year":"2015","journal-title":"Adv. Mater."},{"issue":"8","key":"10.1016\/j.addr.2022.114177_b0455","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.tips.2018.06.003","article-title":"MMP-Responsive \u2018Smart\u2019 Drug Delivery and Tumor Targeting","volume":"39","author":"Yao","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.addr.2022.114177_b0460","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/2570154","article-title":"Proteases Revisited: Roles and Therapeutic Implications in Fibrosis","volume":"2017","author":"Kryczka","year":"2017","journal-title":"Mediators Inflamm."},{"issue":"27","key":"10.1016\/j.addr.2022.114177_b0465","doi-asserted-by":"crossref","first-page":"7870","DOI":"10.1016\/j.biomaterials.2014.05.054","article-title":"Scavenger receptor-recognized and enzyme-responsive nanoprobe for fluorescent labeling of lysosomes in live cells","volume":"35","author":"Fan","year":"2014","journal-title":"Biomaterials"},{"issue":"10","key":"10.1016\/j.addr.2022.114177_b0470","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.7150\/thno.15647","article-title":"Cancer theranostic nanoparticles self-assembled from amphiphilic small molecules with equilibrium shift-induced renal clearance","volume":"6","author":"Ma","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.addr.2022.114177_b0475","doi-asserted-by":"crossref","first-page":"120791","DOI":"10.1016\/j.biomaterials.2021.120791","article-title":"Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity","volume":"272","author":"Yang","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2022.114177_b0480","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.1038\/s41467-020-19970-9","article-title":"Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death","volume":"11","author":"Hayashi","year":"2020","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.addr.2022.114177_b0485","doi-asserted-by":"crossref","first-page":"e631","DOI":"10.1038\/cddis.2013.156","article-title":"Many faces of DAMPs in cancer therapy","volume":"4","author":"Krysko","year":"2013","journal-title":"Cell Death Dis."},{"issue":"7","key":"10.1016\/j.addr.2022.114177_b0490","doi-asserted-by":"crossref","first-page":"12086","DOI":"10.1021\/acsnano.1c03416","article-title":"Visible-light-triggered prodrug nanoparticles combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy","volume":"15","author":"Choi","year":"2021","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.addr.2022.114177_b0495","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/sj.cdd.4402269","article-title":"Molecular characteristics of immunogenic cancer cell death","volume":"15","author":"Tesniere","year":"2008","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.addr.2022.114177_b0500","doi-asserted-by":"crossref","unstructured":"J. Vakkila, M.T.J.N.R.I. Lotze, Inflammation and necrosis promote tumour growth, 4 (2004) 641-648.","DOI":"10.1038\/nri1415"},{"key":"10.1016\/j.addr.2022.114177_b0505","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.addr.2022.114177_b0510","doi-asserted-by":"crossref","unstructured":"J. Peng, Q. Yang, Y. Xiao, K. Shi, Q. Liu, Y. Hao, F. Yang, R. Han, Z. Qian, Tumor Microenvironment Responsive Drug-Dye-Peptide Nanoassembly for Enhanced Tumor-Targeting, Penetration, and Photo-Chemo-Immunotherapy, Advanced Functional Materials, 29 (2019) 1900004.","DOI":"10.1002\/adfm.201900004"},{"key":"10.1016\/j.addr.2022.114177_b0515","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2022.114177_b0520","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jconrel.2021.01.009","article-title":"The right timing, right combination, right sequence, and right delivery for cancer immunotherapy","volume":"331","author":"Kwon","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2022.114177_b0525","doi-asserted-by":"crossref","unstructured":"X. Zhu, C. Li, Y. Lu, Y. Liu, D. Wan, D. Zhu, J. Pan, G.J.A.B. Ma, Tumor microenvironment-activated therapeutic peptide-conjugated prodrug nanoparticles for enhanced tumor penetration and local T cell activation in the tumor microenvironment, 119 (2021) 337-348.","DOI":"10.1016\/j.actbio.2020.11.008"},{"key":"10.1016\/j.addr.2022.114177_b0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2020.125995","article-title":"Molecular engineering of anti-PD-L1 peptide and photosensitizer for immune checkpoint blockade photodynamic-immunotherapy","volume":"400","author":"Wang","year":"2020","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.addr.2022.114177_b0535","doi-asserted-by":"crossref","first-page":"38499","DOI":"10.1021\/acsami.0c06872","article-title":"Small morph nanoparticles for deep tumor penetration via caveolae-mediated transcytosis","volume":"12","author":"Zhang","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.addr.2022.114177_b0540","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12951-018-0398-2","article-title":"Advances in redox-responsive drug delivery systems of tumor microenvironment","volume":"16","author":"Guo","year":"2018","journal-title":"Journal of Nanobiotechnology"},{"key":"10.1016\/j.addr.2022.114177_b0545","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-physiol-021119-034627","article-title":"The acidic tumor microenvironment as a driver of cancer","volume":"82","author":"Boedtkjer","year":"2020","journal-title":"Annu. Rev. Physiol."},{"issue":"2","key":"10.1016\/j.addr.2022.114177_b0550","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0169-409X(02)00179-5","article-title":"Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities","volume":"55","author":"Saito","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2022.114177_b0555","doi-asserted-by":"crossref","first-page":"7168","DOI":"10.1002\/anie.201913522","article-title":"A general strategy for macrotheranostic prodrug activation: synergy between the acidic tumor microenvironment and bioorthogonal chemistry","volume":"59","author":"Dong","year":"2020","journal-title":"Angew. Chem. Int. Ed."},{"issue":"2","key":"10.1016\/j.addr.2022.114177_b0560","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0169-409X(01)00227-7","article-title":"Targeted drug conjugates: principles and progress","volume":"53","author":"Garnett","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"10.1016\/j.addr.2022.114177_b0565","doi-asserted-by":"crossref","first-page":"986","DOI":"10.3390\/cancers13050986","article-title":"Oxidative stress in the tumor microenvironment and its relevance to cancer immunotherapy","volume":"13","author":"Aboelella","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.addr.2022.114177_b0570","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nri3423","article-title":"Beyond oxidative stress: an immunologist's guide to reactive oxygen species","volume":"13","author":"Nathan","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2022.114177_b0575","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41577-020-00478-8","article-title":"Redox regulation of immunometabolism","volume":"21","author":"Muri","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2022.114177_b0580","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1021\/acs.accounts.5b00406","article-title":"Disulfide-based multifunctional conjugates for targeted theranostic drug delivery","volume":"48","author":"Lee","year":"2015","journal-title":"Acc. Chem. Res."},{"issue":"8","key":"10.1016\/j.addr.2022.114177_b0585","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1517\/17425247.2015.1005598","article-title":"Preactivated thiomers: their role in drug delivery","volume":"12","author":"Ijaz","year":"2015","journal-title":"Expert Opinion on Drug Delivery"},{"key":"10.1016\/j.addr.2022.114177_b0590","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.addr.2018.07.017","article-title":"Strategies to overcome the polycation dilemma in drug delivery","volume":"136\u2013137","author":"Bernkop-Schn\u00fcrch","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2022.114177_b0595","doi-asserted-by":"crossref","first-page":"7896","DOI":"10.7150\/thno.61337","article-title":"Probing the fluorination effect on the self-assembly characteristics, in vivo fate and antitumor efficacy of paclitaxel prodrug nanoassemblies","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.addr.2022.114177_b0600","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/s41467-018-03779-8","article-title":"The fluorination effect of fluoroamphiphiles in cytosolic protein delivery","volume":"9","author":"Zhang","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2022.114177_b0605","doi-asserted-by":"crossref","first-page":"1904925","DOI":"10.1002\/adfm.201904925","article-title":"Assemblies of peptide-cytotoxin conjugates for tumor-homing chemotherapy","volume":"29","author":"Wang","year":"2019","journal-title":"Adv. Funct. Mater."},{"issue":"30","key":"10.1016\/j.addr.2022.114177_b0610","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1039\/b706682a","article-title":"A trisulfide-linked glycoprotein","author":"Bernardes","year":"2007","journal-title":"Chem. Commun."},{"key":"10.1016\/j.addr.2022.114177_b0615","doi-asserted-by":"crossref","first-page":"1701070","DOI":"10.1002\/advs.201701070","article-title":"Sequentially triggered nanoparticles with tumor penetration and intelligent drug release for pancreatic cancer therapy","volume":"5","author":"He","year":"2018","journal-title":"Adv. Sci."},{"key":"10.1016\/j.addr.2022.114177_b0620","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1021\/ja513034e","article-title":"Dimeric drug polymeric nanoparticles with exceptionally high drug loading and quantitative loading efficiency","volume":"137","author":"Cai","year":"2015","journal-title":"J. Am. Chem. Soc."},{"issue":"45","key":"10.1016\/j.addr.2022.114177_b0625","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc1725","article-title":"Trisulfide bond\u2013mediated doxorubicin dimeric prodrug nanoassemblies with high drug loading, high self-assembly stability, and high tumor selectivity","volume":"6","author":"Yang","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.addr.2022.114177_b0630","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.nantod.2015.11.004","article-title":"Selenium\/tellurium containing polymer materials in nanobiotechnology","volume":"10","author":"Cao","year":"2015","journal-title":"Nano Today"},{"issue":"4","key":"10.1016\/j.addr.2022.114177_b0635","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3390\/cells6040039","article-title":"Application of sodium selenite in the prevention and treatment of cancers","volume":"6","author":"Kieliszek","year":"2017","journal-title":"Cells"},{"key":"10.1016\/j.addr.2022.114177_b0640","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1021\/ar4000339","article-title":"Selenium-containing polymers: promising biomaterials for controlled release and enzyme mimics","volume":"46","author":"Xu","year":"2013","journal-title":"Acc. Chem. Res."},{"issue":"5","key":"10.1016\/j.addr.2022.114177_b0645","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1021\/ed072p423","article-title":"Bond energy data summarized","volume":"72","author":"Kildahl","year":"1995","journal-title":"J. Chem. Educ."},{"key":"10.1016\/j.addr.2022.114177_b0650","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1038\/s41467-019-11193-x","article-title":"Probing the impact of sulfur\/selenium\/carbon linkages on prodrug nanoassemblies for cancer therapy","volume":"10","author":"Sun","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2022.114177_b0655","doi-asserted-by":"crossref","first-page":"8799","DOI":"10.1021\/ja00780a027","article-title":"Conformational dependence of the electronic energy levels in disulfides","volume":"94","author":"Boyd","year":"1972","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2022.114177_b0660","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.1021\/nl502044x","article-title":"Disulfide bond bridge insertion turns hydrophobic anticancer prodrugs into self-assembled nanomedicines","volume":"14","author":"Wang","year":"2014","journal-title":"Nano Lett."},{"key":"10.1016\/j.addr.2022.114177_b0665","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/08927020701361876","article-title":"Evaluating the stability of disulfide bridges in proteins: a torsional potential energy surface for diethyl disulfide","volume":"33","author":"Haworth","year":"2007","journal-title":"Mol. Simul."},{"key":"10.1016\/j.addr.2022.114177_b0670","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jcis.2020.07.086","article-title":"Redox responsive paclitaxel dimer for programmed drug release and selectively killing cancer cells","volume":"580","author":"Xia","year":"2020","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.addr.2022.114177_b0675","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jconrel.2017.03.391","article-title":"Paclitaxel dimers assembling nanomedicines for treatment of cervix carcinoma","volume":"254","author":"Pei","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2022.114177_b0680","doi-asserted-by":"crossref","unstructured":"W. Li, J. Yang, L. Luo, M. Jiang, B. Qin, H. Yin, C. Zhu, X. Yuan, J. Zhang, Z.J.N.c. Luo, Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death, 10 (2019) 1-16.","DOI":"10.1038\/s41467-019-11269-8"},{"issue":"9","key":"10.1016\/j.addr.2022.114177_b0685","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/nnano.2017.113","article-title":"Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy","volume":"12","author":"Min","year":"2017","journal-title":"Nat. Nanotechnol."},{"issue":"8","key":"10.1016\/j.addr.2022.114177_b0690","first-page":"600","article-title":"Low-dose X-ray radiotherapy\u2013radiodynamic therapy via nanoscale metal\u2013organic frameworks enhances checkpoint blockade immunotherapy, Nature","volume":"2","author":"Lu","year":"2018","journal-title":"Biomed. Eng."},{"key":"10.1016\/j.addr.2022.114177_b0695","doi-asserted-by":"crossref","unstructured":"H. Zhang, D.C. Salo, D.M. Kim, S. Komarov, Y.-C. Tai, M.Y.J.J.o.b.o. Berezin, Penetration depth of photons in biological tissues from hyperspectral imaging in shortwave infrared in transmission and reflection geometries, 21 (2016) 126006.","DOI":"10.1117\/1.JBO.21.12.126006"},{"key":"10.1016\/j.addr.2022.114177_b0700","doi-asserted-by":"crossref","unstructured":"J. Xu, R. Saklatvala, S. Mittal, S. Deshmukh, A.J.A.S. Procopio, Recent progress of potentiating immune checkpoint blockade with external stimuli\u2014An industry perspective, 7 (2020) 1903394.","DOI":"10.1002\/advs.201903394"},{"key":"10.1016\/j.addr.2022.114177_b0705","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41571-020-0410-2","article-title":"Clinical development and potential of photothermal and photodynamic therapies for cancer","volume":"17","author":"Li","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.addr.2022.114177_b0710","doi-asserted-by":"crossref","first-page":"13193","DOI":"10.1038\/ncomms13193","article-title":"Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy","volume":"7","author":"Chen","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2022.114177_b0715","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s40820-020-0378-6","article-title":"Deep-tissue photothermal therapy using laser illumination at NIR-IIa window","volume":"12","author":"Wu","year":"2020","journal-title":"Nano-Micro Lett."},{"key":"10.1016\/j.addr.2022.114177_b0720","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1158\/2326-6066.CIR-17-0055","article-title":"Photodynamic-immune checkpoint therapy eradicates local and distant tumors by CD8<sup>+<\/sup> T cells","volume":"5","author":"Kleinovink","year":"2017","journal-title":"Can. Immunol. Res."},{"key":"10.1016\/j.addr.2022.114177_b0725","doi-asserted-by":"crossref","first-page":"11522","DOI":"10.1002\/anie.201805138","article-title":"Innovative strategies for hypoxic-tumor photodynamic therapy","volume":"57","author":"Li","year":"2018","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.addr.2022.114177_b0730","doi-asserted-by":"crossref","unstructured":"H. Barker, J. Paget, A. Khan, K. Harrington, The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence, 15 (2015) 409\u2013425.","DOI":"10.1038\/nrc3958"},{"key":"10.1016\/j.addr.2022.114177_b0735","doi-asserted-by":"crossref","unstructured":"R.R. Weichselbaum, H. Liang, L. Deng, Y.-X.J.N.r.C.o. Fu, Radiotherapy and immunotherapy: a beneficial liaison?, 14 (2017) 365-379.","DOI":"10.1038\/nrclinonc.2016.211"},{"key":"10.1016\/j.addr.2022.114177_b0740","doi-asserted-by":"crossref","unstructured":"Y. Lee, S.L. Auh, Y. Wang, B. Burnette, Y. Wang, Y. Meng, M. Beckett, R. Sharma, R. Chin, T.J.B. Tu, The Journal of the American Society of Hematology, Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment, 114 (2009) 589-595.","DOI":"10.1182\/blood-2009-02-206870"},{"issue":"8","key":"10.1016\/j.addr.2022.114177_b0745","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.1016\/S1470-2045(19)30157-3","article-title":"Integration of radiotherapy and immunotherapy for treatment of oligometastases","volume":"20","author":"Pitroda","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.addr.2022.114177_b0750","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1172\/JCI31178","article-title":"Indoleamine 2,3-dioxygenase and tumor-induced tolerance","volume":"117","author":"Munn","year":"2007","journal-title":"J. Clin. Investig."},{"issue":"8","key":"10.1016\/j.addr.2022.114177_b0755","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nrd870","article-title":"Endogenous kynurenines as targets for drug discovery and development","volume":"1","author":"Stone","year":"2002","journal-title":"Nat. Rev. Drug Discovery"},{"key":"10.1016\/j.addr.2022.114177_b0760","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1182\/blood-2012-08-449413","article-title":"Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer","volume":"122","author":"Zhang","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.addr.2022.114177_b0765","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.2174\/138161212799504830","article-title":"Physiology, pharmacology and pathophysiology of the ph regulatory transport proteins NHE1 and NBCn1: similarities, differences, and implications for cancer therapy","volume":"18","author":"Boedtkjer","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.addr.2022.114177_b0770","first-page":"6449","article-title":"Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review","volume":"49","author":"Vaupel","year":"1989","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.addr.2022.114177_b0775","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1021\/mp100253e","article-title":"pH-responsive nanoparticles for drug delivery","volume":"7","author":"Gao","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2022.114177_b0780","doi-asserted-by":"crossref","unstructured":"Y. Gu, Y. Zhong, F. Meng, R. Cheng, C. Deng, Z.J.B. Zhong, Acetal-linked paclitaxel prodrug micellar nanoparticles as a versatile and potent platform for cancer therapy, 14 (2013) 2772-2780.","DOI":"10.1021\/bm400615n"},{"issue":"22","key":"10.1016\/j.addr.2022.114177_b0785","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1039\/C4TB00128A","article-title":"A novel nanoassembled doxorubicin prodrug with a high drug loading for anticancer drug delivery","volume":"2","author":"Xu","year":"2014","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.addr.2022.114177_b0790","doi-asserted-by":"crossref","unstructured":"R. Kuai, W. Yuan, S. Son, J. Nam, Y. Xu, Y. Fan, A. Schwendeman, J.J.J.S.a. Moon, Elimination of established tumors with nanodisc-based combination chemoimmunotherapy, Science Advances, 4 (2018) eaao1736.","DOI":"10.1126\/sciadv.aao1736"},{"key":"10.1016\/j.addr.2022.114177_b0795","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jconrel.2021.11.006","article-title":"Tyrosine kinase inhibitor prodrug-loaded liposomes for controlled release at tumor microenvironment","volume":"340","author":"Salmaso","year":"2021","journal-title":"J. Control. Release"},{"issue":"8","key":"10.1016\/j.addr.2022.114177_b0800","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.3390\/nano10081613","article-title":"pH-Responsive Nanoparticles for Cancer Immunotherapy: A Brief Review","volume":"10","author":"Yan","year":"2020","journal-title":"Nanomaterials"},{"key":"10.1016\/j.addr.2022.114177_b0805","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1021\/acs.accounts.0c00475","article-title":"Nano-immune-engineering approaches to advance cancer immunotherapy: lessons from ultra-pH-sensitive nanoparticles","volume":"53","author":"Li","year":"2020","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.addr.2022.114177_b0810","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2020.100924","article-title":"Carrier-free nanoassembly of doxorubicin prodrug and siRNA for combinationally inducing immunogenic cell death and reversing immunosuppression","volume":"35","author":"Chen","year":"2020","journal-title":"Nano Today"},{"key":"10.1016\/j.addr.2022.114177_b0815","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jconrel.2020.09.035","article-title":"Rational design of a minimalist nanoplatform to maximize immunotherapeutic efficacy: Four birds with one stone","volume":"328","author":"Zhou","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2022.114177_b0820","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.trecan.2018.02.005","article-title":"Reengineering the physical microenvironment of tumors to improve drug delivery and efficacy: from mathematical modeling to bench to bedside","volume":"4","author":"Stylianopoulos","year":"2018","journal-title":"Trends in Cancer"},{"key":"10.1016\/j.addr.2022.114177_b0825","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/sj.bjc.6602626","article-title":"Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx\u2122) in human osteosarcoma xenografts","volume":"93","author":"Eikenes","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.addr.2022.114177_b0830","doi-asserted-by":"crossref","unstructured":"K. Beckenlehner, S. Bannke, T. Spru\u00df, G. Bernhardt, H. Sch\u00f6nenberger, W.J.J.o.c.r. Schiess, c. oncology, Hyaluronidase enhances the activity of adriamycin in breast cancer models in vitro and in vivo, 118 (1992) 591-596.","DOI":"10.1007\/BF01211802"},{"key":"10.1016\/j.addr.2022.114177_b0835","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1158\/1535-7163.MCT-10-0470","article-title":"Enzymatic Depletion of Tumor Hyaluronan Induces Antitumor Responses in Preclinical Animal Models","volume":"9","author":"Thompson","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.addr.2022.114177_b0840","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1021\/acs.nanolett.6b00068","article-title":"Hyaluronidase to enhance nanoparticle-based photodynamic tumor therapy","volume":"16","author":"Gong","year":"2016","journal-title":"Nano Lett."},{"key":"10.1016\/j.addr.2022.114177_b0845","doi-asserted-by":"crossref","unstructured":"S. Hingorani, A. Bullock, T. Seery, L. Zheng, D. Sigal, P. Ritch, F. Braiteh, M. Zalupski, N. Bahary, W.J.A.o.O. Harris, PEGPH20 improves pfs in patients with metastatic pancreatic ductal adenocarcinoma: A randomized phase 2 study in combination with nab-paclitaxel\/gemcitabine, 28 (2017) iii137-iii138.","DOI":"10.1093\/annonc\/mdx262.002"},{"key":"10.1016\/j.addr.2022.114177_b0850","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/j.drudis.2020.06.029","article-title":"Engineering extracellular matrix to improve drug delivery for cancer therapy","volume":"25","author":"He","year":"2020","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.addr.2022.114177_b0855","doi-asserted-by":"crossref","unstructured":"H. Zhou, Z. Fan, J. Deng, P.K. Lemons, D.C. Arhontoulis, W.B. Bowne, H.J.N.l. Cheng, Hyaluronidase embedded in nanocarrier PEG shell for enhanced tumor penetration and highly efficient antitumor efficacy, 16 (2016) 3268-3277.","DOI":"10.1021\/acs.nanolett.6b00820"},{"issue":"10","key":"10.1016\/j.addr.2022.114177_b0860","doi-asserted-by":"crossref","first-page":"11008","DOI":"10.1021\/acsnano.9b02395","article-title":"Collagenase nanoparticles enhance the penetration of drugs into pancreatic tumors","volume":"13","author":"Zinger","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2022.114177_b0865","doi-asserted-by":"crossref","first-page":"119616","DOI":"10.1016\/j.biomaterials.2019.119616","article-title":"Extracellular matrix-penetrating nanodrill micelles for liver fibrosis therapy","volume":"230","author":"Fan","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2022.114177_b0870","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.biomaterials.2016.06.048","article-title":"Cyclopamine disrupts tumor extracellular matrix and improves the distribution and efficacy of nanotherapeutics in pancreatic cancer","volume":"103","author":"Zhang","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2022.114177_b0875","doi-asserted-by":"crossref","unstructured":"V.P. Chauhan, J.D. Martin, H. Liu, D.A. Lacorre, S.R. Jain, S.V. Kozin, T. Stylianopoulos, A.S. Mousa, X. Han, P.J.N.c. Adstamongkonkul, Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels, 4 (2013) 1-11.","DOI":"10.1038\/ncomms3516"},{"key":"10.1016\/j.addr.2022.114177_b0880","doi-asserted-by":"crossref","unstructured":"S. Snipstad, K. Vikedal, M. Maardalen, A. Kurbatskaya, E. Sulheim, C.J.A.D.D.R. de Lange Davies, Ultrasound and microbubbles to beat barriers in tumors: improving delivery of nanomedicine, 177 (2021) 113847.","DOI":"10.1016\/j.addr.2021.113847"},{"key":"10.1016\/j.addr.2022.114177_b0885","doi-asserted-by":"crossref","unstructured":"G. Dimcevski, S. Kotopoulis, T. Bj\u00e5nes, D. Hoem, J. Schj\u00f8tt, B.T. Gjertsen, M. Biermann, A. Molven, H. Sorbye, E.J.J.o.C.R. McCormack, A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer, 243 (2016) 172-181.","DOI":"10.1016\/j.jconrel.2016.10.007"},{"key":"10.1016\/j.addr.2022.114177_b0890","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.addr.2008.03.005","article-title":"Microbubbles in ultrasound-triggered drug and gene delivery","volume":"60","author":"Hernot","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2022.114177_b0895","doi-asserted-by":"crossref","unstructured":"M. Afadzi, O.F. Myhre, P.T. Yemane, A. Bj\u00f8rk\u00f8y, S.H. Torp, A.v. Wamel, S. Lelu, B.A.J. Angelsen, C.d.L. Davies, Effect of Acoustic Radiation Force on the Distribution of Nanoparticles in Solid Tumors, IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, 68 (2021) 432-445.","DOI":"10.1109\/TUFFC.2020.3027072"},{"key":"10.1016\/j.addr.2022.114177_b0900","doi-asserted-by":"crossref","unstructured":"S. Lee, H. Han, H. Koo, J.H. Na, H.Y. Yoon, K.E. Lee, H. Lee, H. Kim, I.C. Kwon, K.J.J.o.C.R. Kim, Extracellular matrix remodeling in vivo for enhancing tumor-targeting efficiency of nanoparticle drug carriers using the pulsed high intensity focused ultrasound, 263 (2017) 68-78.","DOI":"10.1016\/j.jconrel.2017.02.035"},{"issue":"3","key":"10.1016\/j.addr.2022.114177_b0905","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1021\/acs.nanolett.7b05087","article-title":"Peptide-functionalized phase-transformation nanoparticles for low intensity focused ultrasound-assisted tumor imaging and therapy","volume":"18","author":"Zhu","year":"2018","journal-title":"Nano Lett."},{"issue":"5706","key":"10.1016\/j.addr.2022.114177_b0910","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.addr.2022.114177_b0915","doi-asserted-by":"crossref","unstructured":"T.P. Padera, B.R. Stoll, J.B. Tooredman, D. Capen, E. di Tomaso, R.K.J.N. Jain, Cancer cells compress intratumour vessels, 427 (2004) 695-695.","DOI":"10.1038\/427695a"},{"issue":"2","key":"10.1016\/j.addr.2022.114177_b0920","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1039\/C6MD00614K","article-title":"Encapsulation of a nitric oxide donor into a liposome to boost the enhanced permeation and retention (EPR) effect","volume":"8","author":"Tahara","year":"2017","journal-title":"Med. Chem. Commun."},{"key":"10.1016\/j.addr.2022.114177_b0925","doi-asserted-by":"crossref","unstructured":"P.G. Wang, M. Xian, X. Tang, X. Wu, Z. Wen, T. Cai, A.J.J.C.r. Janczuk, Nitric oxide donors: chemical activities and biological applications, 102 (2002) 1091-1134.","DOI":"10.1021\/cr000040l"},{"key":"10.1016\/j.addr.2022.114177_b0930","doi-asserted-by":"crossref","first-page":"119297","DOI":"10.1016\/j.biomaterials.2019.119297","article-title":"Tumor vasodilation by N-Heterocyclic carbene-based nitric oxide delivery triggered by high-intensity focused ultrasound and enhanced drug homing to tumor sites for anti-cancer therapy","volume":"217","author":"Kang","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2022.114177_b0935","article-title":"Vasodilator Hydralazine Promotes Nanoparticle Penetration in Advanced Desmoplastic Tumors","author":"Chen","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2022.114177_b0940","doi-asserted-by":"crossref","unstructured":"K. Park, Facing the truth about nanotechnology in drug delivery, 7 (2013) 7442-7447.","DOI":"10.1021\/nn404501g"},{"key":"10.1016\/j.addr.2022.114177_b0945","doi-asserted-by":"crossref","unstructured":"M. Hidalgo, F. Amant, A.V. Biankin, E. Budinsk\u00e1, A.T. Byrne, C. Caldas, R.B. Clarke, S. de Jong, J. Jonkers, G.M.J.C.d. M\u00e6landsmo, Patient-derived xenograft models: an emerging platform for translational cancer research, 4 (2014) 998-1013.","DOI":"10.1158\/2159-8290.CD-14-0001"},{"issue":"3","key":"10.1016\/j.addr.2022.114177_b0950","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.1997.15.3.987","article-title":"Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation","volume":"15","author":"Muggia","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2022.114177_b0955","doi-asserted-by":"crossref","first-page":"103384","DOI":"10.1016\/j.jri.2021.103384","article-title":"Potential toxicity of nanoparticles on the reproductive system animal models: A review","volume":"148","author":"Ajdary","year":"2021","journal-title":"J. Reprod. Immunol."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X22000679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X22000679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:23:35Z","timestamp":1759209815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X22000679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":191,"alternative-id":["S0169409X22000679"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2022.114177","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor-activated carrier-free prodrug nanoparticles for targeted cancer Immunotherapy: Preclinical evidence for safe and effective drug delivery","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2022.114177","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114177"}}